Independent directory Public ClinicalTrials.gov records United States
Clinical Trials Finder
Objective public record navigation
Search Results

Search by objective public record fields.

Search by query text, NCT ID, condition, intervention, sponsor, city, state, recruitment status, phase, study type, healthy volunteer eligibility, sex, or age. Results come from ClinicalTrials.gov. When the live registry is unavailable, a clearly labeled stored copy may be shown.

Clear filters

These results were retrieved from the live ClinicalTrials.gov registry. Filters and sort order apply to this result list.

ClinicalTrials.gov public records Last synced Oct 20, 2026, 4:09 PM EDT

Data is sourced from official ClinicalTrials.gov public API records. Always review the official ClinicalTrials.gov record for the latest information.

Showing 1–24 of 32 matching trials from the live ClinicalTrials.gov search.
Filters: Intervention: GLP-1 Low Dose Clear all
Completed Phase 2 Interventional Results available

Feasibility Trial Testing the Bionic Pancreas With ZP4207

NCT02971228
View directory record Official record
Conditions
Diabetes Mellitus, Type 1
Interventions
Insulin Lispro, ZP4207 (dasiglucagon), Glucagon, iPhone-based bionic pancreas, iLet-based bionic pancreas
Drug · Device
Lead sponsor
Zealand Pharma
Industry
Eligibility
18 Years and older
Enrollment
13 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2016 – 2017
U.S. locations
1
States / cities
Boston, Massachusetts
Source: ClinicalTrials.gov public record
Updated Mar 23, 2021 · Synced Oct 20, 2026, 4:09 PM EDT
Completed No phase listed Observational Accepts healthy volunteers

PET-CT Scan Method to Monitor Pancreatic B-Cell Loss in Diabetes Mellitus

NCT00633763
View directory record Official record
Conditions
Type1 Diabetes Mellitus
Interventions
18F-fallypride
Drug
Lead sponsor
University of California, Irvine
Other
Eligibility
18 Years and older
Enrollment
30 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2008
U.S. locations
1
States / cities
Orange, California
Source: ClinicalTrials.gov public record
Updated May 29, 2009 · Synced Oct 20, 2026, 4:09 PM EDT
Not yet recruiting Phase 4 Interventional

Comparing Different Medication Regimens to Maintaining Weight Loss Among Adults With Obesity Using GLP-1s

NCT07832084
View directory record Official record
Conditions
Obesity & Overweight, Cardiometabolic Health Indicators
Interventions
GLP-1 dose reduction, non-GLP weight loss medication, Maintenance of GLP-1 dose, Resistance exercise regimen, Lifestyle/nutrition counseling
Drug · Behavioral
Lead sponsor
Jing Luo
Other
Eligibility
18 Years and older
Enrollment
60 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2026 – 2028
U.S. locations
1
States / cities
Pittsburgh, Pennsylvania
Source: ClinicalTrials.gov public record
Updated Oct 5, 2026 · Synced Oct 20, 2026, 4:09 PM EDT
Completed Phase 3 Interventional Results available

A Study to Evaluate Tirzepatide (LY3298176) in Pediatric and Adolescent Participants With Type 2 Diabetes Mellitus Inadequately Controlled With Metformin or Basal Insulin or Both

NCT05260021
View directory record Official record
Conditions
Type2 Diabetes, Diabetes Mellitus, Diabetes Mellitus, Type 2, T2D, T2DM (Type 2 Diabetes Mellitus), Glucose Metabolism Disorders, Endocrine System Diseases, Metabolic Disease
Interventions
Tirzepatide Dose 1, Tirzepatide Dose 2, Placebo
Drug
Lead sponsor
Eli Lilly and Company
Industry
Eligibility
10 Years to 18 Years
Enrollment
99 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2022 – 2025
U.S. locations
13
States / cities
Los Angeles, California • Sacramento, California • San Diego, California + 10 more
Source: ClinicalTrials.gov public record
Updated Sep 26, 2025 · Synced Oct 20, 2026, 4:09 PM EDT
Recruiting Phase 2Phase 3 Interventional

Effectiveness of Alternative Therapies in Maintaining Weight Loss Achieved by GLP-1 Medications Post-Cessation

NCT07092618
View directory record Official record
Conditions
Longevity, GLP-1, Geroscience, Aging
Interventions
Metformin, Rapamycin, Naltrexone, Vitamin C
Drug · Dietary Supplement
Lead sponsor
AgelessRx
Industry
Eligibility
40 Years to 85 Years
Enrollment
150 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2024 – 2025
U.S. locations
1
States / cities
Chicago, Illinois
Source: ClinicalTrials.gov public record
Updated Jul 30, 2025 · Synced Oct 20, 2026, 4:09 PM EDT
Completed Phase 4 Interventional Results available

Semaglutide Treatment, Appetite, and Eating Behavior: Long-term Effects

NCT05548647
View directory record Official record
Conditions
Obesity
Interventions
Behavioral Treatment, Placebo, Semaglutide 2.4 MG/0.75 ML Subcutaneous Solution [WEGOVY]
Behavioral · Drug
Lead sponsor
University of Pennsylvania
Other
Eligibility
18 Years to 70 Years
Enrollment
120 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2022 – 2025
U.S. locations
1
States / cities
Philadelphia, Pennsylvania
Source: ClinicalTrials.gov public record
Updated Aug 3, 2026 · Synced Oct 20, 2026, 4:09 PM EDT
Enrolling by invitation Early Phase 1 Interventional Accepts healthy volunteers

Effectiveness of Microdosed GLP-1 in Improving Health, Quality of Life, and Longevity Measures

NCT07092605
View directory record Official record
Conditions
Longevity, Quality of Life, Mood, Inflammation, Immune Health, Pain Management, Weight Management, Alertness
Interventions
GLP-1, Placebo
Drug
Lead sponsor
AgelessRx
Industry
Eligibility
18 Years to 65 Years
Enrollment
150 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2024 – 2025
U.S. locations
1
States / cities
Ann Arbor, Michigan
Source: ClinicalTrials.gov public record
Updated Jul 30, 2025 · Synced Oct 20, 2026, 4:09 PM EDT
Active, not recruiting Phase 2 Interventional

A Study to Assess Efficacy, Safety, Tolerability, Pharmacokinetics (PK) and Pharmacodynamics (PD) of RO7204239 in Combination With Tirzepatide in Participants With Obesity or Overweight With At Least One Weight-related Comorbidity

NCT06965413
View directory record Official record
Conditions
Obesity, Overweight, Overweight With One Weight Related Comorbidity
Interventions
RO7204239, RO7204239 Matching Placebo, Tirzepatide
Drug
Lead sponsor
Hoffmann-La Roche
Industry
Eligibility
18 Years and older
Enrollment
285 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2025 – 2027
U.S. locations
19
States / cities
Anniston, Alabama • Spring Valley, California • Clermont, Florida + 16 more
Source: ClinicalTrials.gov public record
Updated Sep 9, 2026 · Synced Oct 20, 2026, 4:09 PM EDT
Terminated Phase 4 Interventional Accepts healthy volunteers Results available

Changes in Bone Turnover With Exposure to a GLP-1 Receptor Agonist

NCT01381926
View directory record Official record
Conditions
Type 2 Diabetes Mellitus, Bone Remodeling
Interventions
exenatide, Saline
Drug
Lead sponsor
University of Alabama at Birmingham
Other
Eligibility
45 Years and older · Female only
Enrollment
14 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2011 – 2015
U.S. locations
1
States / cities
Birmingham, Alabama
Source: ClinicalTrials.gov public record
Updated Jun 14, 2017 · Synced Oct 20, 2026, 4:09 PM EDT
Active, not recruiting Phase 1 Interventional Accepts healthy volunteers

Liver Glycogen and Hypoglycemia in Humans

NCT03241706
View directory record Official record
Conditions
Hypoglycemia; Iatrogenic
Interventions
Low Fructose, Saline, Somatostatin, Insulin, Glucagon, Dextrose solution, High Fructose
Drug
Lead sponsor
Jason Winnick
Other
Eligibility
21 Years to 40 Years
Enrollment
40 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2018 – 2028
U.S. locations
1
States / cities
Cincinnati, Ohio
Source: ClinicalTrials.gov public record
Updated Jul 25, 2025 · Synced Oct 20, 2026, 4:09 PM EDT
Recruiting Phase 1 Interventional

Semaglutide Delivered Epi-Intradermally by Microarray Patch (VX-201) Versus Subcutaneous Administration in Healthy Overweight and Obese Participants

NCT07673900
View directory record Official record
Conditions
Overweight and/or Obesity
Interventions
VX-201, semaglutide SC
Combination Product · Drug
Lead sponsor
Terrestrial Bio, Inc.
Industry
Eligibility
18 Years to 60 Years
Enrollment
62 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2026 – 2027
U.S. locations
1
States / cities
Tempe, Arizona
Source: ClinicalTrials.gov public record
Updated Jul 31, 2026 · Synced Oct 20, 2026, 4:09 PM EDT
Completed Phase 2 Interventional Results available

A Study to Evaluate the Efficacy and Safety of MEDI0382 in the Treatment of Overweight and Obese Subjects With Type 2 Diabetes

NCT03235050
View directory record Official record
Conditions
Diabetes Mellitus, Type 2
Interventions
MEDI0382 low dose, MEDI0382 mid dose, MEDI0382 high dose, Placebo, Liraglutide
Drug
Lead sponsor
AstraZeneca
Industry
Eligibility
18 Years to 130 Years
Enrollment
834 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2017 – 2019
U.S. locations
22
States / cities
Birmingham, Alabama • Chandler, Arizona • Glendale, Arizona + 17 more
Source: ClinicalTrials.gov public record
Updated Aug 17, 2020 · Synced Oct 20, 2026, 4:09 PM EDT
Recruiting Not applicable Interventional Accepts healthy volunteers

Slowly Digestible Carbohydrates for GLP-1 Secretion

NCT07572513
View directory record Official record
Conditions
Blood Glucose, GLP-1, Satiety, Second Meal Intake, Healthy Participant Study
Interventions
Maltodextrin (Placebo), Raw Corn Starch
Dietary Supplement
Lead sponsor
Purdue University
Other
Eligibility
18 Years to 45 Years
Enrollment
19 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2026
U.S. locations
1
States / cities
West Lafayette, Indiana
Source: ClinicalTrials.gov public record
Updated May 7, 2026 · Synced Oct 20, 2026, 4:09 PM EDT
Recruiting Phase 2 Interventional

GLP-1R Agonist Treatment for Opioid Use Disorder

NCT06548490
View directory record Official record
Conditions
Opioid Use Disorder, Opioid Abuse and Addiction, Narcotic-Related Disorders, Substance-Related Disorders, Chemically-Induced Disorders, Mental Disorder, Opioid
Interventions
Semaglutide Pen Injector, Placebo
Drug
Lead sponsor
Milton S. Hershey Medical Center
Other
Eligibility
18 Years to 75 Years
Enrollment
200 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2025 – 2027
U.S. locations
4
States / cities
Baltimore, Maryland • Fall River, Massachusetts • New York, New York + 1 more
Source: ClinicalTrials.gov public record
Updated Aug 28, 2026 · Synced Oct 20, 2026, 4:09 PM EDT
Completed Not applicable Interventional

Effect of Supplement on Appetite and GLP-1

NCT06790771
View directory record Official record
Conditions
Hunger
Interventions
High Dose Supplement, Low Dose Supplement, Placebo
Dietary Supplement
Lead sponsor
Texas Christian University
Other
Eligibility
18 Years to 60 Years
Enrollment
25 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2025 – 2026
U.S. locations
1
States / cities
Fort Worth, Texas
Source: ClinicalTrials.gov public record
Updated May 28, 2026 · Synced Oct 20, 2026, 4:09 PM EDT
Completed Phase 1Phase 2 Interventional Results available

Use of a GLP-1R Agonist to Treat Opioid Use Disorder

NCT04199728
View directory record Official record
Conditions
Opiate Substitution Treatment, Opioid-Related Disorders
Interventions
Liraglutide Pen Injector, Placebo
Drug
Lead sponsor
Milton S. Hershey Medical Center
Other
Eligibility
18 Years to 75 Years
Enrollment
27 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2021 – 2023
U.S. locations
1
States / cities
Hershey, Pennsylvania
Source: ClinicalTrials.gov public record
Updated Nov 6, 2024 · Synced Oct 20, 2026, 4:09 PM EDT
Completed Not applicable Interventional Results available

Physiologic Response to Glucagon at Varying Insulin Levels

NCT01483651
View directory record Official record
Conditions
Type 1 Diabetes Mellitus
Interventions
Glucagon, Insulin
Drug
Lead sponsor
Legacy Health System
Other
Eligibility
21 Years to 65 Years
Enrollment
11 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2011 – 2013
U.S. locations
1
States / cities
Portland, Oregon
Source: ClinicalTrials.gov public record
Updated Mar 29, 2016 · Synced Oct 20, 2026, 4:09 PM EDT
Completed Phase 1 Interventional

A Study of the Safety, Tolerability, Pharmacokinetics and Pharmacodynamic Activity of Very Low Dose-Glucagon in Subjects With Type 1 Diabetes Mellitus

NCT00304538
View directory record Official record
Conditions
Type 1 Diabetes
Interventions
very low dose (VLD) glucagon
Drug
Lead sponsor
DiObex
Industry
Eligibility
18 Years to 55 Years
Enrollment
10 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2006
U.S. locations
1
States / cities
San Diego, California
Source: ClinicalTrials.gov public record
Updated Aug 23, 2006 · Synced Oct 20, 2026, 4:09 PM EDT
Completed Phase 1 Interventional Accepts healthy volunteers

Dose-response Study of Exendin-9,39 on Glucose Metabolism

NCT01218633
View directory record Official record
Conditions
Pancreatic Effects of 9,39-Exendin and 9,36-GLP-1
Interventions
saline infusion, GLP-1-9,36 infusion, Exendin-9,39 at low dose, Exendin-9,39 at high dose
Drug
Lead sponsor
Adrian Vella
Other
Eligibility
20 Years to 45 Years
Enrollment
11 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2011 – 2012
U.S. locations
1
States / cities
Rochester, Minnesota
Source: ClinicalTrials.gov public record
Updated Jan 23, 2013 · Synced Oct 20, 2026, 4:09 PM EDT
Withdrawn Phase 1 Interventional

Dexamethasone/Pancreatic Clamp P&F

NCT06126354
View directory record Official record
Conditions
Insulin Resistance, Prediabetic State, Non-Alcoholic Fatty Liver Disease, Overweight and Obesity
Interventions
Insulin human, Octreotide Acetate, Glucagon, Human Growth Hormone, Dexamethasone Oral, [6,6-2H2] D-glucose, 20% D-glucose (aq), BOOST Plus, Harvard Apparatus PHD ULTRA CP syringe pump, Yellow Springs Instruments (YSI) 2500 Biochemistry Glucose/Lactate Analyzer, Normal saline, Human albumin
Drug · Other · Dietary Supplement + 1 more
Lead sponsor
Columbia University
Other
Eligibility
18 Years to 65 Years
Healthy volunteers
Healthy volunteers not accepted
Timeline
2024 – 2026
U.S. locations
1
States / cities
New York, New York
Source: ClinicalTrials.gov public record
Updated Jul 10, 2024 · Synced Oct 20, 2026, 4:09 PM EDT
Active, not recruiting Phase 1 Interventional Accepts healthy volunteers

Effect of Prolonged (72 Hour) Glucagon Administration on Energy Expenditure in Healthy Obese Subjects

NCT03139305
View directory record Official record
Conditions
Obesity
Interventions
Glucagon, Placebo
Drug
Lead sponsor
AdventHealth Translational Research Institute
Other
Eligibility
18 Years to 55 Years
Enrollment
30 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2017 – 2027
U.S. locations
1
States / cities
Orlando, Florida
Source: ClinicalTrials.gov public record
Updated Mar 30, 2026 · Synced Oct 20, 2026, 4:09 PM EDT
Completed Phase 1Phase 2 Interventional

Metabolic Effects of Non-Nutritive Sweeteners

NCT01200940
View directory record Official record
Conditions
Healthy Volunteers
Interventions
Sucralose, Aspartame, Acesulfame-Potassium, Control
Other
Lead sponsor
National Institute of Diabetes and Digestive and Kidney Diseases (NIDDK)
NIH
Eligibility
6 Years and older
Enrollment
118 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2010 – 2017
U.S. locations
1
States / cities
Bethesda, Maryland
Source: ClinicalTrials.gov public record
Updated Jan 22, 2021 · Synced Oct 20, 2026, 4:09 PM EDT
Not yet recruiting Phase 2 Interventional

Semaglutide for Low Back Pain

NCT07731256
View directory record Official record
Conditions
Lower Back Pain, Obesity (BMI>30), Chronic Lower Back Pain, glp1 Agonist
Interventions
Semaglutide (administered by PDS290 pen-injector), Placebo (administered by PDS290 pen-injector)
Drug
Lead sponsor
Washington University School of Medicine
Other
Eligibility
18 Years to 85 Years
Enrollment
250 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2027 – 2031
U.S. locations
2
States / cities
Birmingham, Alabama • St Louis, Missouri
Source: ClinicalTrials.gov public record
Updated Jul 28, 2026 · Synced Oct 20, 2026, 4:09 PM EDT
Completed Phase 4 Interventional Results available

Liraglutide Effects on Epicardial Fat Inflammatory Genes

NCT03260881
View directory record Official record
Conditions
Type2 Diabetes, Coronary Artery Disease
Interventions
Liraglutide Pen Injector [Victoza], matching liraglutide-placebo pre-filled pens
Drug
Lead sponsor
University of Miami
Other
Eligibility
18 Years and older
Enrollment
38 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2018 – 2024
U.S. locations
1
States / cities
Miami, Florida
Source: ClinicalTrials.gov public record
Updated Jul 8, 2025 · Synced Oct 20, 2026, 4:09 PM EDT